Fiera Capital Corp Sells 28,679 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Fiera Capital Corp reduced its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 554,200 shares of the biopharmaceutical company's stock after selling 28,679 shares during the period. Fiera Capital Corp owned about 0.73% of Xenon Pharmaceuticals worth $21,819,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Harbor Capital Advisors Inc. grew its position in shares of Xenon Pharmaceuticals by 647.8% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 24,116 shares of the biopharmaceutical company's stock worth $940,000 after buying an additional 20,891 shares during the last quarter. Capital International Investors grew its position in shares of Xenon Pharmaceuticals by 0.8% in the 1st quarter. Capital International Investors now owns 2,475,859 shares of the biopharmaceutical company's stock worth $106,586,000 after buying an additional 20,176 shares during the last quarter. Westfield Capital Management Co. LP grew its position in shares of Xenon Pharmaceuticals by 46.3% in the 1st quarter. Westfield Capital Management Co. LP now owns 347,351 shares of the biopharmaceutical company's stock worth $14,953,000 after buying an additional 109,856 shares during the last quarter. DNB Asset Management AS grew its position in shares of Xenon Pharmaceuticals by 39.2% in the 2nd quarter. DNB Asset Management AS now owns 175,733 shares of the biopharmaceutical company's stock worth $6,852,000 after buying an additional 49,483 shares during the last quarter. Finally, Driehaus Capital Management LLC grew its position in shares of Xenon Pharmaceuticals by 2.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company's stock worth $172,315,000 after buying an additional 97,732 shares during the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock traded down $0.74 during mid-day trading on Friday, hitting $45.00. The company's stock had a trading volume of 332,239 shares, compared to its average volume of 385,756. Xenon Pharmaceuticals Inc. has a 52-week low of $27.99 and a 52-week high of $50.99. The business has a 50-day moving average price of $40.97 and a 200 day moving average price of $40.29. The stock has a market cap of $3.41 billion, a price-to-earnings ratio of -16.42 and a beta of 1.25.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.05). During the same period in the previous year, the firm posted ($0.72) earnings per share. Equities research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on XENE shares. Wedbush cut their price objective on Xenon Pharmaceuticals from $50.00 to $49.00 and set an "outperform" rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price target on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. William Blair upgraded Xenon Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. HC Wainwright began coverage on Xenon Pharmaceuticals in a research report on Tuesday, October 1st. They set a "buy" rating and a $53.00 price target on the stock. Finally, Royal Bank of Canada restated an "outperform" rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. Eleven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Xenon Pharmaceuticals currently has an average rating of "Buy" and an average target price of $57.45.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.